Oramed Pharmaceuticals has started recruiting patients for a new clinical trial of ORMD-0801, an orally ingestible insulin capsule, for patients with type 1 diabetes mellitus (T1DM) in Israel.
Clinical stage biopharmaceutical company DiaMedica has completed enrollment of type 2 diabetic patients in the DM199 single ascending dose (SAD) clinical study.
Diffusion Pharmaceuticals has completed enrolling 56 patients with newly diagnosed primary brain cancer (glioblastoma multiforme or GBM) in the Phase II trial of an anti-cancer compound, trans sodium crocetinate (TSC).
Avaxia Biologics has treated the first patient in a Phase1b clinical study using AVX drug dosage, designed for the treatment of ulcerative colitis.
Eli Lilly and Company has reported positive data from the Phase III study of Cialis/finasteride in men with lower urinary tract symptoms of benign prostatic hyperplasia (LUTS/BPH) and enlarged prostates.
Boston Therapeutics has presented positive results of its PAZ320 drug, designed for reducing post-meal elevation of blood glucose, from its Phase ll clinical trial.
CSL Behring has commenced the patient enrollment in pivotal pediatric Phase III hemophilia B study of recombinant fusion protein linking coagulation factor IX with recombinant albumin (rIX-FP).